[go: up one dir, main page]

MX2017012449A - Tratamiento del dolor. - Google Patents

Tratamiento del dolor.

Info

Publication number
MX2017012449A
MX2017012449A MX2017012449A MX2017012449A MX2017012449A MX 2017012449 A MX2017012449 A MX 2017012449A MX 2017012449 A MX2017012449 A MX 2017012449A MX 2017012449 A MX2017012449 A MX 2017012449A MX 2017012449 A MX2017012449 A MX 2017012449A
Authority
MX
Mexico
Prior art keywords
individual
pain treatment
pain
managing
managing pain
Prior art date
Application number
MX2017012449A
Other languages
English (en)
Inventor
Alexander Barden Julian
Original Assignee
Biosceptre Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901215A external-priority patent/AU2015901215A0/en
Application filed by Biosceptre Uk Ltd filed Critical Biosceptre Uk Ltd
Publication of MX2017012449A publication Critical patent/MX2017012449A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método de tratamiento del dolor en un individuo, que incluye las siguientes etapas: proporcionar un individuo que necesita tratamiento del dolor; administrar un anticuerpo anti-receptor P2X7 al individuo; tratando de ese modo el dolor en el individuo.
MX2017012449A 2015-04-02 2016-04-01 Tratamiento del dolor. MX2017012449A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901215A AU2015901215A0 (en) 2015-04-02 Pain treatment
AU2015901216A AU2015901216A0 (en) 2015-04-02 Pain treatment
PCT/AU2016/050249 WO2016154683A1 (en) 2015-04-02 2016-04-01 Pain treatment

Publications (1)

Publication Number Publication Date
MX2017012449A true MX2017012449A (es) 2018-02-21

Family

ID=57003686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012449A MX2017012449A (es) 2015-04-02 2016-04-01 Tratamiento del dolor.

Country Status (9)

Country Link
US (1) US20180037650A1 (es)
EP (1) EP3277726A4 (es)
JP (2) JP6790062B2 (es)
CN (1) CN107614528A (es)
AU (1) AU2016240410B2 (es)
BR (1) BR112017020783A8 (es)
CA (1) CA2980788A1 (es)
MX (1) MX2017012449A (es)
WO (1) WO2016154683A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180043841A (ko) 2015-09-11 2018-04-30 카리나 바이오테크 피티와이 엘티디 키메라 항원 수용체 및 이의 용도
WO2018071959A1 (en) 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles
MX2023015028A (es) * 2021-09-01 2024-02-16 Biosceptre Aust Pty Ltd Nuevos aglutinantes del p2x7 disfuncional.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028022A2 (en) * 2005-09-01 2007-03-08 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
WO2007109201A2 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0915367B8 (pt) * 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
ES2557456T3 (es) * 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
JP5992831B2 (ja) * 2009-12-24 2016-09-14 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
US9562094B2 (en) * 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
WO2013178783A1 (en) * 2012-06-01 2013-12-05 Ablynx N.V. P2x7 receptor antagonists and agonists
WO2018071959A1 (en) * 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles

Also Published As

Publication number Publication date
JP6790062B2 (ja) 2020-11-25
JP2021014460A (ja) 2021-02-12
CN107614528A (zh) 2018-01-19
EP3277726A1 (en) 2018-02-07
AU2016240410A1 (en) 2017-09-28
JP7096558B2 (ja) 2022-07-06
AU2016240410B2 (en) 2021-09-16
EP3277726A4 (en) 2018-08-22
WO2016154683A1 (en) 2016-10-06
JP2018514583A (ja) 2018-06-07
BR112017020783A8 (pt) 2022-08-02
US20180037650A1 (en) 2018-02-08
CA2980788A1 (en) 2016-10-06
BR112017020783A2 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
EA201790398A1 (ru) Способы лечения заболевания печени
CL2016000354A1 (es) Modulación de la inmunidad tumoral
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
AR095882A1 (es) Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
SA516370641B1 (ar) مركبات حلقية غير متجانسة وطرق لاستخدامها
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
MX365403B (es) Peptidos y metodos para usarlos.
TW201613975A (en) Methods for treating multiple myeloma
MX2017003691A (es) Metodos para tratar lupus eritematoso sistemico usando un anticuerpo de dominio dirigido contra cd28.
ZA202503387B (en) Semaglutide in medical therapy
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
EP3581205A3 (en) Product and method for treating diarrhea
MX2018016103A (es) Metodos para manejar los efectos adversos en poblaciones de pacientes que necesitan una transfusion.
MX2017012449A (es) Tratamiento del dolor.
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.
MX2016011706A (es) Formulaciones de progesterona.
IL252239A0 (en) Chronic pain management methods and hcg therapy
MA40574A (fr) Traitement de maladies fibrotiques
UA89943U (uk) Спосіб прискорення провідності нервово-м'язового імпульсу в спортсменів
UA84302U (ru) Способ коррекции иммунного статуса у больных рекуррентным депрессивным расстройством
IN2014MU01245A (es)